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1011-105 How Does Myocardial Inducible Nitric Oxide Synthase 
Gene Expression Relate to Heart Failure Severity and to 
Subsequent Left Ventricular Reverse Remodeling in 
Patients With Chronic Heart Failure?
W. H. Wilson Tang, Fernando Lopez, Y. Gail Yee, Anne Mullin, Ying Zhang, Michael B. 
Fowler, Stanford University, Stanford, CA
Background: Previous work has shown that patients with advanced HF have higher lev-
els of mNOS2 gene expression compared to normal controls. We examined mNOS2
expression in patients with varying degrees of HF severity and examined the relationship
between mNOS2 expression and subsequent reverse remodeling.
Methods: We performed endomyocardial biopsies on 45 ambulatory patients with
chronic HF (NYHA II-III, LV ejection fraction (LVEF) <45%). To quantify the severity of HF,
plasma NT-proBNP (Roche) was measured during the procedure. Intensity of mNOS2
gene expression was determined using quantitative TaqMan RT-PCR (in ng/mg tissue).
Reverse remodeling was estimated by change in LVEF, determined by serial echo >6
months apart.
Results: Myocardial NOS2 expression correlated inversely with plasma NT-proBNP lev-
els (r= –0.40, p=0.02, see Figure), but not with baseline LVEF (r=0.09, p=0.56). Further-
more, mNOS2 expression correlated directly with improvement in LVEF (r=0.50, p=0.03)
in the subset of patients with echo follow-up (n=19).
Conclusions: Low levels of mNOS2 expression are associated with more advanced HF
and decreased likelihood of subsequent LV reverse remodeling in patients with chronic
HF. These observations do not support the hypothesis that increased mNOS2 expression
impairs LV function and leads to the progression of HF. Rather, increased mNOS2
expression identifies a subset of patients with advanced HF who still have the potential
for subsequent reverse remodeling.
1011-106 One-Minute Heart Rate Recovery After Cycloergometer-
Exercise Test as a Predictor of Mortality in a Cohort of 
1,420 Real-Life Exercise Test Candidates: Substantial 
Differences With the Treadmill Derived Parameter
Nicola Gaibazzi, Nicola Petrucci, Vigilio Ziacchi, Ospedale Civile, Desenzano del Garda-
BS, Italy
Background: Previous studies have shown a strong reverse association between one-
minute heart rate recovery(1min-HRR) after exercising on a treadmill and all-cause mor-
tality.We sought to determine whether the results could be replicated in a large popula-
tion of "real world" exercise-ECG candidates, using a standard bicycle exercise test.
Methods and Results: 1,420 consecutive patients underwent ECG exercise-test using
our standard cycloergometer protocol between 1991 and 1997. We tested 3 pre-speci-
fied cutpoint-values of 1min-HRR, derived from previous studies using treadmill(Kaplan-
Meier curves for one of these values are reported in Fig.1) to check whether they could
discriminate a higher-risk group for all-cause mortality; furthermore we tested the possi-
ble association between 1min-HRR as a continuous variable and mortality, using logistic
regression. Both statistical methods showed lack of statistically significant association
between 1min-HRR and all-cause mortality.A weak trend towards inverse association,
although not statistically significant, could not be excluded.
Conclusion: We could not validate the clear-cut results from some previous studies per-
formed using treadmill exercise-test.Results of our study only can not exclude a mild
inverse association between 1min-HRR measured after cycloergometer exercise-test
and all-cause mortality.1min-HRR measured after cycloergometer exercise-test should
probably be discarded as a clinically useful prognostic marker.
1011-107 Enhanced Left Ventricular Systolic Function Early in 
Type II Diabetic Mice
Jorge A. Alvarez, Maricela Reyes, Mark E. Steinhelper, Danny Escobedo, Gregory 
Freeman, Marc D. Feldman, University of Texas Health Science Center, San Antonio, TX
Background: Early in type II Diabetes(DM) the heart is exposed to increased levels of
the substrates glucose and free fatty acids. While isolated heart studies have shown
increased relation between left ventricular(LV) function and substrate concentration,
echocardiography of the intact mice model show decrease in LV function. In genetic mod-
els of DM since LV function is load sensitive, the true state of LV function in early DM
remains unknown. Thus, we hypothesize that early in DM there is enhanced LV systolic
function due to increased energy supply.
Methods: Type II Diabetic mice (BKS.Cg-m +/+ Leprdb (db/db, n = 7) and paired non-dia-
betic wildtype (WT, n = 9) were sedated with ip Etomidate and Urethane, intubated, and
subjected to thoracotomy. A miniaturized LV catheter(Millar, TX) and dual frequency con-
ductance system were used. Ascending aortic flow was determined (Transonics, NY) for
calibration. LV pressure-volume relations were defined at rest and transient occlusion of
the aorta. Body and heart weight were recorded.
Results: Despite greater body weight, the db/db mice had the same heart weight and
afterload as the WT. An enhancement of LV contractility is shown in the table for the db/
db mice in 4 of 5 parameters examined.
Discussion: We show for the first time, using load independent technique to study intact
mice, that early in Diabetes LV contraction is enhanced. This suggests that a positive
relation between circulating substrate level and myocardial performance is present in vivo
in this condition.
1011-108 Cardiac Responses to Intracoronary-Delivered Stem 
Cells in Apolipoprotein-Null Mice: Assessment by 
Langendorff Perfusion
Shu Li, Jing Lin, Eric Lenehan, Mitra Rajabi, Rosalinda Madonna, Corina Rosales, 
James T. Willerson, Yong J. Geng, The University of Texas Medical School at Houston, 
Houston, TX, Texas Heart Institute, Houston, TX
Background: Apolipoprotein-E (apoE-/-) mice develop hypercholesterolemia eventually
leading to atherosclerosis and ischemic heart failure. Stem cell therapy has been impli-
cated for treating patients with heart failure. This study aimed at determining the efficacy
of cardiac stem cell therapy in an atherosclerosis-prone animal model.
Methods: The hearts of apoE-/- (n=6) and wild type C57BL/6J (n=12) mice were isolated
and perfused with bisbensimide-labeled embryonic stem cells (ESCs) via a Langendorff
device. The hemodaynamic parameters, e.g. coronary flow (CF), heart rate (HR), left
ventricular peak pressure (LVP), +dp/dtmax, and -dp/dtmax, were recorded at different
time points before, during and after ESCs perfusion.
Results: Both apoE-/- and wild type mouse hearts underwent similar cardiac functional
Control Diabetic P value
BW (g) 23 ± 1 48 ± 1 0.00001
HW (mg) 114 ± 3 110 ± 5 0.54
HR (bpm) 471 ± 16 495 ± 13 0.30
Pmax (mmHg) 82 ± 4 121 ± 5 0.00001
EF (%) 53 ± 5 64 ± 5 0.20
Ea (mmHg/µl) 10 ±  3 15 ±  4 0.30
Power/EDV(mWatts/µl2) 91 ± 24 189 ± 32 0.03
dp/dtmax(mmHg/sec) 6,531 ± 1126 11,669 ± 902 0.003
PRSW (mmHg) 69 ± 11 107 ± 9 0.02
E'max(mmHg/µl) 20 ±  6 137 ±  43 0.03
dp/dt-EDV (mmHg x µl/sec) 457 ± 132 1,020 ± 251 0.07
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changes in response to coronary ESC perfusion, including declines in CF, HR, LVP, +dp/
dtmax, and –dp/dtmax, with increased ESC perfusion rates. However, the magnitude of
these parameters differed between the two mouse strains. At less than 106 cells/ml/min,
the percent decline of these parameters in wild type hearts appeared significantly greater
(p<0.05) than those of apoE-/-: CF 15.2% in wild type vs. 10% in apoE-/-, HR 19% vs.
7%, LVP 9% vs. 6%, +dp/dtmax 11% vs. 8%, and –dp/dtmax 24% vs. 11%. Increasing
the perfusion rates up to 5x106 cells/ml/min led to further deterioration of the heart func-
tions but the apoE-/- hearts remained lower levels of the parameter declines. Histopatho-
logical analysis showed the presence of numerous ESC in microcirculation as well as in
the extravascular tissue.
Conclusions: Perfusion with ESC through coronary arteries causes concentration-
dependent changes in heart function. Compared to wild type controls, the hearts of
apoE-/- mice which underwent atherosclerosis-related chronic ischemia appeared to be
better tolerant to high ESC perfusion.
1011-109 The Mitochondrial Metabolic Phenotype and Mouse 
Strain Influence Isoproterenol-Induced Cardiac 
Hypertrophy
Michael Faulx, Michael S. Zawaneh, Margaret P. Chandler, William C. Stanley, Brian D. 
Hoit, Case Western Reserve University, Cleveland, OH, University Hospitals of 
Cleveland, Cleveland, OH
Introduction We previously described a novel model of isoproterenol (ISO)-induced
hypertrophy in which A/J mice exhibit greater cardiac hypertrophy than B6 mice. The
objective of this study was to determine the relation between this variable hypertrophic
response and the mitochondrial metabolic phenotype.
Methods 39 male mice (19 A/J, 20 B6) received randomly either ISO (100 mg/kg, sc) or
vehicle daily for five days. Hearts were assayed for the genomically-expressed mitochon-
drial enzymes pyruvate dehydrogenase (PDH), medium chain acyl-CoA dehydrogenase
(MCAD), carnitine palmitoyl transferase I (CPT-I) and citrate synthase activities. Nine
consomic B6.AM mice (B6 containing mitochondrial DNA from A/J) were also studied.
Results ISO-treated A/J mice displayed a greater increase in gravimetric heart/body
weight (vs. vehicle) than ISO-treated B6 (24% vs. 3%, respectively, p<0.001). Enzyme
activities were greater in vehicle-treated B6 than A/J mice (Table). ISO administration
reduced active PDH activity (PDHa) in B6 mice by 47% (p<0.001), with no significant
change in A/J. The hypertrophic response and basal and stimulated enzyme activites
were similar in B6.AM and B6 mice.
Conclusions 1) Compared to A/J, B6 mice demonstrate less ISO-induced cardiac hyper-
trophy, but greater activity of fatty acid and carbohydrate oxidative enzymes. 2) ISO-
induced hypertrophy reduces myocardial PDH in a strain-dependent manner. 3) These
mitochondrial enzyme activities are not influenced by mitochondrial DNA.
1011-110 The HNO/Nitric Oxide Donor Angeli’s Salt Enhances 
Myocyte Contractility in a PKA-Dependent Manner
Carlo G. Tocchetti, Tatsuo Katori, Manuela Zaccolo, Daniele Mancardi, Diego F. Belardi, 
Katrina M. Miranda, David A. Wink, David A. Kass, Nazareno Paolocci, Johns Hopkins 
University, Baltimore, MD, NIH, Bethesda, MD
Background: Nitroxyl anion (HNO/NO-) donors exert similar positive inotropic/lusitropic
effects in normal and failing hearts in vivo that are not reproduced by NO/nitrate donors.
These effects are partly linked to calcitonin gene-related peptide (CGRP) release. We
hypothesize that the HNO/NO- donor Angeli’s Salt (AS) has a direct positive inotropic
effect on myocyte contractility.
Methods: Cardiac myocytes were isolated from wild type 1-4 month old mice, sus-
pended in Tyrode’s solution (1.8 mM calcium) and field stimulated at 0.5 Hz at 23°C. Sar-
comere shortening (SS) was assessed by real-time image analysis, and Ca2+ transients
from Indo-1 fluorescence. Data are presented at steady-state (10 minutes AS infusion).
Results: AS induced a dose-dependent inotropic response (SS: +17±3% at 0.1 mM,
n=5; +28±7% at 0.25 mM, n=9; +89±12% at 0.5 mM, n=8; +135±21% at 1 mM, n=11; all
p<0.01 versus baseline). Peak Ca2+ transients increased +18±7% at 0.25 mM (p=0.05,
n=5). To test a role of Protein Kinase A (PKA) stimulation by AS, experiments were
repeated in the presence of the PKA-inhibitor H89 (5 µM). AS-induced inotropy was fully
reversed by H89 (-100±33%) at 0.5 mM AS, and partially blunted (-74±42%) at 1 mM
(both n=4). In striking contrast, 10 min infusion of the NO-donor DEA/NO at 0.05 and
0.125 mM (equivalent to 0.1 and 0.25 mM AS) reduced SS -63±6% (p<0.001 vs AS 0.1
mM, n=5) and -21±11% (p=0.002 vs AS 0.25 mM, n=8), respectively, without altering
Ca2+ transients. Higher DEA/NO doses did not depress contractility, but yielded insignifi-
cant changes that remained well below the positive effects of AS (e.g. 33±16% at DEA/
NO 0.5 mM, <20% of the AS 1 mM response, p=0.001, n=16).
Conclusion: The HNO/NO- donor AS directly enhances myocyte contractility in a dose-
dependent manner that differs markedly from NO-donors. AS inotropy is coupled to an
increase in Ca2+ transients and blunted by PKA inhibition, supporting involvement of
cAMP/PKA dependent signaling.
1011-111 Homocysteine Promotes Ventricular Remodeling by 
Induction of Apoptosis of Rabbit Cardiomyocytes and 
Priming the Mast Cells to Induce Interleukin-6, With 
Significant Inhibition by Troglitazone
Bahaeddin A. Shabaneh, Wassim Mouannes, Steven Lee, Matthew Fitzgerald, Kenton 
Hall, Steve Armstrong, Guha Krishnaswamy, East Tennessee State University, Johnson 
City, TN
Background:
Homocysteine (HCy) has been linked to the pathophysiology of atherosclerosis, on the
other hand, it has been linked to ventricular remodeling and heart failure through pro-
inflammatory causes. This may occur due to direct effects on the cardiomyocytes or indi-
rectly by involving other cells like macrophages, fibroblasts and mast cells.
Methods:
After isolating rabbit cardiomyocytes ( CMs ) using the standard perfusion method, we
have given d,l HCy ( 1x 10-4 M ) to the cells and at three hours we quantitated the apop-
totic cells using Flow Cytometry. We used Annexin V ( FITC ) - Propidium Iodide method
for apoptosis detection. Apoptotic cells manifest as Annexin V - FITC positive and Propid-
ium Iodide negative, while necrotic cells manifest as Annexin V - FITC positive and PI
positive. We have also given d,l HCy to Human Leukemic Mast Cells (HMC-1) with 1 ng/
mL of Interleukin 1 beta ( IL1b ) in a dose dependent manner ( 10, 50 , 100 x 10-6 M). We
added the Peroxisome Proliferator Activated Receptors (PPAR) gamma agonist ( Troglita-
zone ) to the cells as well ( 10 x10-6 M ). We used ELISA technique to quantitate the
amount of Interleukin 6 ( IL 6 ) in the supernatants after 24 hours of incubation.
Results:
We found that d,l HCy induces apoptosis of CMs in the HCy group ( 3.0% versus 1.0 %
control , p = 0.02 ) . On the other hand, we noticed a dose dependent increase in IL 6
concentration in response to stimulation of HMC1 cell line with a small fixed dose of IL1b
and increasing doses of d,l Hcy ( 35 pg/mL versus 75 pg/mL , for IL1b alone versus IL1b
+ HCY 100x10-6 , p= 0.004). Surprisingly, adding Troglitazone to the HCy - IL1b - HMC-1
solution blunted the stimulatory response ( 35 pg/mL versus 15 pg/mL, p =0.045 ). Low
concentration Troglitazone in a separate study did not kill HMC-1 cell line per flow cytom-
etry and viability methods.
Conclusions:
HCy induces apoptosis of rabbit cardiomyocytes, and to our knowledge this is the first
experiment that documents this finding . Moreover, HCy primes the mast cells to the
effects of IL1b to produce IL6, this was blunted by PPAR inhibition. Apoptosis and IL6 are
involved in ventricular remodeling and heart failure. Further testing is warranted to study
the various effects of HCy on cardiomyocytes.
1011-112 Use of Abciximab Prior to Primary Angioplasty in ST-
Segment Elevation Myocardial Infarction Results in 
Early Recanalization of the Infarct-Related Artery: 
Results of the Multicenter Randomized ReoPro-
BRIDGING Study
Mariann Gyongyosi, Hans Domanovits, Birgit Heinisch, Wolfgang Benzer, Morritz Haugk, 
Kurt Huber, The ReoPro-BRIDGING Study Group, University of Vienna, Vienna, Austria
Background. The ReoPro-BRIDGING Austrian multicenter randomized study investi-
gated the effect of Abciximab (ReoPro) on infarct-related artery (IRA) patency and early
reperfusion prior to primary coronary intervention (pPCI).
Methods. Thirty-eight patients with ST-segment elevation AMI were treated with ReoPro
0.25 mg/kg bolus followed by 10 ug/min infusion and randomized either to start ReoPro
during the organization time (66±33 min) for pPCI (Group 1, n=18) or immediately after
pPCI (Group 2, n=20). Serial measurements of creatine kinase (CK), CKMB, myoglobin,
and 12-lead ECG were performed at baseline as well as 2, 4, 6, 8, 10, 12, 24 and 48 h
thereafter.
Results. A trend to a more rapid and higher release of cardiac enzymes was observed in
patients of Group 1: rate of rise of CK 164±203 vs 127±170 U/l/min; CKmax: 922±954 vs
776±644 U/L, CKMBmax: 120±72 vs 105±85 U/l and myoglobin max. 1399±1092 vs
909±943 ng/ml (Fig.1). ST-segment resolution >50% occurred in 12 patients (67%) in
Group 1 and 6 patients (30%) in Group 2 (p=0.024) before pPCI. TIMI flow 0 was
observed in 6 (33%) vs 11 patients (55%) of Group 1 vs 2 (p=0.3). Corrected TIMI frame
count was significantly lower (57±33 vs 76±22 frames, p=0.034) and angiographic mini-
mal lumen diameter was larger (0.70±0.76 vs 0.29±0.39 mm, p=0.020) in patients of
Group 1.
Conclusions. Use of ReoPro in the organization phase for pPCI results in early and bet-
ter recanalization of the infarct-related artery prior to pPCI with a consecutive rapid
release of cardiac enzymes.
Data are mean ± SEM. * p<0.01 B6 vs. A/J by ANOVA. † p<0.001 ISO vs. 
vehicle by t-test.
A/J vehicle B6 vehicle A/J ISO B6 ISO
Citrate synthase (µmol/min/gww) 59 ±  4 171 ±  5 * 56 ±  3 163 ±  6
MCAD (µmol/min/gww) 10.4 ±  1.1 11.7 ±  0.9 * 8.9 ±  0.9 13.2 ±  0.9
CPT-1 (µmol/min/gww) 1.7 ±  0.1 2.4 ±  0.2 * 1.5 ±  0.1 2.4 ±  0.2
PDH active (U/gww) 2.2 ±  0.4 4.8 ±  0.5 * 1.9 ±  0.3 2.5 ±  0.3 †
